To include your compound in the COVID-19 Resource Center, submit it here.

Centocor gets rights to DDDP's thrombin inhibitors

Centocor, a subsidiary of Johnson & Johnson (JNJ), acquired worldwide rights

Read the full 110 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE